FARO Academy

Introduction: Harnessing the Immunological Potential of Dogs

In recent years, dogs have emerged as a powerful and underutilized host species for monoclonal antibody discovery, particularly when it comes to generating antibodies against canine-relevant antigens, large proteins, and complex conformational structures.

The diverse immune repertoire and robust antibody responses of dogs make them particularly valuable for generating antibodies that are challenging to obtain from traditional models such as mice or rabbits.

• Custom antigen design, peptide synthesis, and protein engineering
• Tailored canine immunization protocols
• Immune, naïve, or synthetic phage display library construction using canine-derived sequences
• High-throughput phage display library screening
• Clone validation with binding and specificity assays
• Recombinant antibody expression and purification
• Optional Fc engineering and isotype switching
• in vivo validation support (if needed)

 

That's why we offer two scientifically rigorous, complementary workflows to discover high-quality monoclonal antibodies suitable for canine applications:

① one based on direct canine immunization and phage display screening, and

② another using murine hybridoma-derived antibodies followed by canine-specific engineering.

These dual paths allow our clients to choose the most appropriate method depending on antigen complexity, downstream application, and available pre-existing reagents.

• Canine-based discovery via immune/synthetic phage display libraries
  or
• Mouse hybridoma development followed by antibody caninization (framework engineering for compatibility in canines)